Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy
Not yet recruitingOBSERVATIONAL
Enrollment
450
Participants
Timeline
Start Date
May 31, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Conditions
Non-Metastatic Breast Carcinoma
Interventions
OTHER
No intervention
No intervention added by the study
All Listed Sponsors
lead
Assistance Publique - Hôpitaux de Paris
OTHER
NCT06418139 - Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy | Biotech Hunter | Biotech Hunter